A new federal watchdog report is calling on agencies to improve their policies that govern the drug scheduling process—including how they evaluate substances and develop recommendations. The new U.S. Government Accountability Office (GAO) report published on Wednesday comes as the federal government continues to consider whether to comprehensively reschedule marijuana under the Controlled Substances Act (CSA) to Schedule III as was recommended by the Department of Health and Human Services (HHS). In general, GAO found that the Drug Enforcement Administration's (DEA) scheduling decisions usually aligned with HHS and Food and Drug Administration (FDA) recommendations during the period of six years that it examined—but that both agencies lack important procedures for carrying out their responsibilities and to ensure consistency in the process.

Angela Paxton accused Ken Paxton of adultery in divorce filings but has been publicly silent about her view of his race. On Friday, she spoke to a group of Republican women in a speech called the “Ele...

Only some of the bets will allow margin trading, showing where the prediction-markets platform thinks its future lies.

The grand jury reviewing the death of Nolan Wells has found that, based on all the evidence they reviewed, no criminal charges are warranted at this point.